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Highlights 
• 
Higher prevalence of Autism Spectrum Disorder (14.8%) in DMD boys. 
• 
Higher prevalence of Intellectual Disability (36.2%) in DMD. 
• 
Higher prevalence of CBCL Internalizing Problems (23.4%) in DMD. 
• 
First study in DMD based on reliable psychopathological assessment. 
• 




To evaluate through a comprehensive protocol, the psychopathological profile of DMD boys. The 
primary aim of this observational study was to describe the emotional and behavioural profile and 
the neurodevelopmental problems of Italian boys with Duchenne Muscular Dystrophy (DMD); the 
secondary aim was to explore the relation between psychopathological profile and DMD genotype. 
Method 
47 DMD boys, aged 2–18, were included in the study and assessed through structured and validated 
tools including Wechsler scales or Griffiths for cognitive ability, Child Behavior Check List 
(CBCL), Youth Self Report (YSR) and Strengths and Difficulties Questionnaire (SDQ) for 
emotional and behavioural features. Patients “at risk” based on questionnaires scores were 
evaluated by a clinical structured interview using Development and Well Being Assessment 
(DAWBA) or Autism Diagnostic Observation Schedule (ADOS), as required. 
Results 
The 47 enrolled patients, defined with a Full Scale Intelligence Quotient (FSIQ) of 80.38 (one SD 
below average), and presenting a large and significant difference in FSIQ in relation to the site of 
mutation along the dystrophin gene (distal mutations associated with a more severe cognitive 
deficit), were showing Internalizing Problems (23.4%) and Autism Spectrum Disorders (14.8%). 
Interestingly, an association of internalizing problems with distal deletion of the DMD gene is 
documented. 
Conclusion 
Even though preliminary, these data show that the use of validated clinical instruments, that focus 
on the impact of emotional/behaviour problems on everyday life, allows to carefully identify 
clinically significant psychopathology. 
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1. Introduction 
Duchenne muscular dystrophy (DMD) is an X-linked progressive muscular disorder 
affecting about 1:3000 boys caused by genetic mutations disrupting the protein dystrophin 
(DYS), which is normally present in many human tissues, especially in muscle. Lack of 
DYS leads to progressive muscular weakness and death due to respiratory muscle 
insufficiency.1 DYS also plays an important role in the architectural organization of the 
central nervous system and has some functional consequences,2 i.e., disruption of normal 
synaptic terminal integrity, synaptic plasticity and regional cellular signal integration.3 
Clinical literature consistently reports a higher rate of intellectual disabilities (ID; ranging 
from 20% to 50%) among DMD patients.4; 5; 6 ;  7 The cognitive impairment is neither 
progressive nor correlated with the severity of the muscle disease. A discrepancy between 
verbal intelligence quotient (VIQ) and performance IQ (PIQ) has often been found, with 
greater impairment of verbal components. Such findings hint at the possibility that the lack 
of dystrophin might have effects on the correct brain functioning, leading to cognitive 
impairments as well as neurobehavioral disorders.8 
The occurrence of psychopathology in patients with DMD has been documented in several 
studies. In a recent multicenter study focused on neurodevelopmental, emotional and 
behavioural characteristics in DMD a high prevalence of autism spectrum disorder (ASD; 
21%), hyperactivity (24%), inattention (44%), internalizing (24%) and externalizing 
problems (15%) has been found.9 These results are in line with previous studies on 
neurobehavioral functioning in DMD, which report a higher prevalence of attention deficit 
hyperactivity disorder (ADHD) and ASD than expected in the general population. 
The prevalence rate of ADHD in patients with DMD reported in the literature varies from 
11.7%10 to 33%,11 ;  12 whereas ASD prevalence rate ranges from 3.79% to 19%.10; 12; 
13; 14; 15 ;  16 Variability in prevalence rate across different studies possibly reflects 
different methods used to assess the presence of the psychopathological diagnosis. The 
importance of detecting mental disorders in children and adolescents is widely accepted, and 
the accurate estimate of the prevalence of psychopathology for these age groups is essential, 
both in the general population and in children with a specific illness. 
The above-mentioned studies have used an assessment method based on clinical evaluations 
rather than structured interviews. However, structured or semi-structured interviews become 
necessary to accurately assess the prevalence of psychopathology in specific child 
populations as well as in general population. Structured interviews, besides collecting 
emotional and behavioural problems, provide specific questions about the onset, offset, 
frequency, intensity, quality, context of occurrence, and functional impairment, thus they are 
needed to determine clinical cases or to produce accurate diagnoses17 according to the main 
nosologic classifications (i.e., DSM-IV or V, ICD 10). 
The main purpose of the current study is to describe the emotional and behavioural profile 
and the neurodevelopmental problems of boys with DMD, using structured clinical 
assessment based both on self-report questionnaires and clinical structured interviews or 
observational protocol, when needed. In addition, this study aims to explore the relation 
between psychopathological profile and DMD neurological phenotype. 
2. Materials and methods 
2.1. Procedure 
To assess emotional and behavioural features, all parents completed the Child Behavior 
Checklist (CBCL) and the Strength and Difficulties Questionnaire (SDQ) parent-report 
form. In addition, patients up to 11 years old completed the Youth Self Report (YSR) and 
the SDQ self-report form. Patients with at least one CBCL/YSR syndrome scale or SDQ 
scale above the clinical cut-off were evaluated by a clinical structured interview using the 
Development and Well Being Assessment diagnostic interview (DAWBA). Patients with 
high scores on the Autism Spectrum Problems CBCL 1/5-5 scale and patients with a clinical 
diagnosis of ASD based on DSM-IV-TR criteria were further assessed with structured 
observation based on the Autism Diagnostic Observation Schedule (ADOS). 
The study was approved by the Ethical Committee of the E. Medea Scientific Institute 




A clinical population of 133 boys with DMD (aged from 2.8 to 32 years) attend each year 
the Neuromuscular Unit of IRCCS E. Medea for periodic clinical evaluation as indicated in 
international guidelines.1 Among these, 52 boys were responding to the inclusion criteria 
(see below) and were recruited during their attendance at the Institute as in patients or 
outpatients. Fifty patients and their families agreed to participate in the research and parents 
signed a written informed consent form, 47 completed the study. 
Inclusion criteria were age between 2 and 18 years and diagnosis of DMD according to 
international standard criteria: progressive muscular weakness, increased muscle plasma 
enzymes, muscular biopsy and/or the presence of mutations in the dystrophin gene.1 
Clinical conditions (including cardiac function, steroid treatment, and motor function) and 
demographic features (including age, family structure, and socioeconomic status) were 
collected. 
We used parental employment as a measure of SES coded according to the Hollingshead 9-
point scale for parental occupation.18 
2.3. Measures 
2.3.1. Cognitive assessment 
Cognitive ability was assessed using the Wechsler Intelligence Scale (WISC-III or WIPPSI) 
or Griffiths scale as required based on the patient's age. 
2.3.2. Psychiatric comorbidity based on self-reported questionnaires 
Emotional and behavioural problems and their impact on patients' everyday life were 
assessed by Child Behavior Check List 6–18 (CBCL), Youth Self Report (YSR), and 
Strength and Difficulties Questionnaire (SDQ). 
The CBCL 6–1819 is a questionnaire filled out by parents that is designed to assess social 
competence and behavioural problems in children and adolescents aged from 6 to 18 years. 
The CBCL consists of two parts: the first part explores the social competences of children 
and adolescents, and the second part investigates their behavioural and emotional problems, 
through 113 items rated on a 3-point: 0 = not true, 1 = somewhat or sometimes true and 
2 = very true or often true. The CBCL includes 8 cross-informant syndrome scales 
(Anxious/Depressed, Withdrawn/Depressed, Somatic Complaints, Social Problems, 
Thought Problems, Attention Problems, Rule-Breaking Behaviour, and Aggressive 
Behaviour), two broadband scales (Internalizing, made up of Withdrawn, Somatic 
Complaints, and Anxious/Depressed scales, and Externalizing, made up of Rule-Breaking 
Behaviour and Aggressive Behaviour), and a Total Problem scale. YSR is a self-report 
version of the ASEBA questionnaire15 that is addressed to children and adolescents aged 
11–18 years. 
SDQ20 is a brief behavioural screening questionnaire addressed to 4–17-year-olds. It 
includes the following components: 25 items on psychological attributes, some positive and 
others negative that are divided among 5 scales with 5 items each (Emotional Symptoms, 
Conduct Problems, Hyperactivity/Inattention, and Peer Relationship Problems), a Total 
difficulties score and a Prosocial Behaviour scale. The impact supplement of the SDQ, 
enquires about chronicity, distress, social impairment, and burden to others of identified 
problems. The impact score ranges from 0 to 10 for the parent and self-report questionnaire. 
2.3.3. Prevalence of psychiatric disorders based on a structured clinical interview or protocol 
observation 
The clinical assessment was conducted using the Development and Well Being Assessment 
diagnostic interview (DAWBA)21 or the Autism Diagnostic Observation Schedule 
(ADOS).22 
The DAWBA combines a structured part and a semi-structured part, and it is designed to 
generate present-state psychiatric diagnoses based on the DSM-IV and ICD 10 criteria for 
children and adolescents. The structured sections explore the following psychopathological 
areas: separation anxiety, simple phobia, social phobia, panic disorder with/without 
agoraphobia, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder, 
generalized anxiety disorder, major depression, attention deficit and hyperactivity disorder, 
behavioural disorder, and less common disorders. The semi-structured part of the interview 
elicits a verbatim account of any reported problems. The DAWBA has satisfactory validity 
and inter-rater reliability. 21 ;  23 The answers to the structured questions from the 
interviews and questionnaires were fed into a computerized diagnostic algorithm. This 
algorithm provided six levels of prediction of the probability of a disorder, ranging from 
very unlikely to probable, the “DAWBA Bands.” The individual is assigned to one of six 
probability bands corresponding to the approximate prevalence in an epidemiological 
sample24 ranging from less than .1% likely to more than 70% likely (the other thresholds 
are .5%, 3%, 15%, and 50%). The interviews were administered by a trained interviewer. 
The ADOS22 is a standardized, semi-structured observational assessment used to assess 
communication, reciprocal social interaction, imagination/creativity, and stereotyped 
behaviours and restricted interests to inform the diagnosis of ASD. The ADOS is organized 
into four modules based on the individual's chronological age and expressive language level, 
ranging from preverbal to verbally fluent. All ADOS assessments were administered and 
scored by a licensed clinical child psychiatrist. 
2.4. Data analysis 
Descriptive statistics were generated for demographic and clinical variables and are reported 
as mean and SD values for continuous variables and frequencies/rates for categorical 
variables. 
To detect the prevalence of psychopathology in the DMD sample group, frequencies/rates of 
clinical syndrome and broadband scales were calculated. According to ASEBA 
Multicultural Manual, we considered clinical range scores corresponding to T > 69 for the 
syndrome scales, and T > 63 for the Internalizing, Externalizing, and Total Problems Scales. 
The level of agreement between the parent report and self-report for each scale was assessed 
by the Pearson correlation coefficient. The correlation between SDQ and CBCL was 
assessed by the Pearson correlation test. 
The association between emotional disorders and genetic profile was assessed by Χ2 test. 
To evaluate possible association of emotional behavioural problems with different clinical 
features of the sample (motor function, steroid treatment, site of mutation, FSIQ, and age), a 
series of t tests was performed on continuous CBCL and YSR t-scale scores. The level of 
significance was set at P < .05. 
Data analysis was performed using SPSS for Windows (version 17.0). 
3. Results 
3.1. Patients and family characteristics 
The clinical and demographic features (including age, family status, and socioeconomic 
status) of the 47 patients completing the study are reported in Table 1. Genetic profile 
(available for 46 boys), wheelchair use, steroid therapy, and presence of cardiomyopathy are 
also reported in Table 1. The mean age of DMD participants was 10.96 years (SD: 3.85, 
range 2–18 y), the mean age of diagnosis was 3.2 (SD: 1.5) all the boys with DMD were 
Caucasian. Families of enrolled patients were mainly biparental (91.5%), and they had a 
medium socioeconomic status. 
At the time of the assessment, 28 out of 47 patients were under current steroid therapy 
(currently treated with deflazacort; 59.57%), 10 out of 47 (21.28%) stopped treatment more 
than 1 year before the beginning of the study, 9 boys were steroid naïve (19.15%). 32 boys 
(68.09%) were wheelchair bound, and 31.9% had a cardiomyopathy. 
The site of mutation along the DMD gene was “proximal” (upstream to exon 44) in 54.35% 
of the whole sample and “distal” (down-stream to exon 44) in 45.65%. 
The mean FSIQ in DMD patients was more than one SD below the mean (80.38), with a 
greater impairment of verbal components (VIQ: 82.88) than of performance components 
(PIQ: 85.83); a large and significant difference in FSIQ between the two types of mutations 
was found (proximal deletion FSIQ: 86.88 vs distal deletion FSIQ: 74.62; t = −2.170; 
p = .035). FSIQ < 70 was seen in 36.2% of the total sample. 
3.2. Prevalence of psychopathology based on self-report questionnaires and structured 
interviews 
The CBCL syndromic and broadband scales t scores (mean and SD) are reported in 
Fig. 2 ;  Fig. 3. In addition, in order to ensure that behavioural outcome data were “clinically 
relevant,” t scores were split into t values above the border cut-off (t value ranging from 65 
to 68 for syndrome scales; t value ranging from 60 to 62 for broadband scales) and t values 
above clinical cut-off (t value up to 69 and 63, respectively). For each scale, the prevalence 
and rate of border and clinical cases were reported. 
As shown in Fig. 2, parent reports t scores were higher than self-reports for each scale. 
However, a large correlation among parent ratings and self-rating was found, according to 
Cohen's criteria. 25 Significant r values were detected for Withdrawn/Depressed (r = .63; 
p < .01), Social Problems (r = .45; p < .05), Thought Problems (r = .59; p < .01), Aggressive 
Behavior (r = .70; p < .01), Internalizing Problems (r = .60; p < .01), Externalizing Problems 
(r = .51; p < .05), and Total Problems (r = .62; p < .01). 
The Internalizing Problems scale together with the Depressed Problems, Anxious/Depressed 
Problems, and Somatic Compliant subscales showed a higher mean score. 
Data from the SDQ Questionnaires showed significant positive correlations with all of the 
CBCL syndrome and broadband subscales (ranging from r = .465, Internalizing Problems, 
to r = .696, Attention Problems). SDQ Hyperactivity scale showed a significant high 
correlation with the Attention Problems CBCL scale (r = .775). In our sample, the SDQ 
Impact Score ranged from 0 to 4 (mean: .26; SD: .759). 
Being in clinical range of CBCL/YSR scales was not associated with the site of mutation 
(χ2 = .877; p = .645). Assessment with the clinical structured interview DAWBA was 
performed on 11 (23.40%) patients (only the parent or both parents and self as required). 
The computerized diagnostic algorithm of DAWBA assessment identified only one patient 
with more than a 70% probability for Social Phobia disorder. In all other cases, although 
some emotional symptoms were confirmed, we found at most the level 2 DAWBA band for 
each psychopathological investigated area, corresponding to a 3% probability of having a 
diagnosis. Indeed, assessed boys did not meet the diagnostic criteria for any specific 
psychopathological disorder according to the DSM-IV. 
Based on protocol criteria, 7 DMD boys (14.89%) were assessed by ADOS; all the boys met 
the criteria for ASD, and 4 of them presented proximal deletion, whereas the other 3 
presented distal deletion on the DMD gene (χ2 = .205; p = .902). The FSIQ was 
significantly lower than in the whole sample (t = 2.462; p = .018), as shown in Table 2. 
3.3. Association of emotional behaviour problems with type of mutation, wheelchair, 
steroid, FSIQ and age 
Data analysis showed that only the CBCL Anxious/Depressed subscale scores were 
significantly higher in patients with distal than proximal deletion (58.20 vs 54.04; t = 2.12; 
p = .04). The same difference was detected on the YSR: boys with distal deletion scored 
significantly higher (46.60 vs 36.60; t = 2.70; p = .015) on the Internalizing Problem Scale. 
Significantly higher Withdrawn/Depressed scores were reported in patients using a 
wheelchair vs not using wheelchair (60.86 vs 55.88; t = 2.10; p = .04). All patients who 
completed the YSR were in a wheelchair, therefore it was not possible to perform this 
comparison on YSR data. 
 
Boys with ID showed significantly higher Withdrawn/Depressed scores (62.87 vs 57.03; 
t = −2.07, p = .04) and Internalizing Problems scores (59.07 vs 52.57; t = −2.08; p = .04), 
but only on the CBCL questionnaire. 
No significant association of either ongoing steroid therapy or age with any CBCL and YSR 
t score scales was found. 
4. Discussion 
In the present study, 47 Italian boys with DMD were assessed for emotional and behavioural 
problems and neurobehavioral disorders. Our assessment method was relying on screening 
questionnaires in the first step and subsequent assessment with clinical structured interviews 
(DAWBA) or observational protocol (ADOS), in order to enhance diagnostic accuracy. 
Several studies found a high level of psychopathological comorbidity in DMD9; 10; 11; 12; 
13; 14; 15 ;  16: these studies frequently did not use recommended assessment methods, 
such as structured or semi-structured interviews that include specific questions about the 
onset, offset, frequency, intensity, quality, context of occurrence, and functional impairment, 
which are necessary elements to determine clinical caseness or to assign a diagnosis.17 In 
fact, most of former studies that investigate psychopathology among DMD patients have 
used an assessment method based on parent-reported questionnaires9; 10; 11; 13; 14 ;  15 or 
clinical evaluations.11; 13 ;  14 Less frequently we found studies including both 
standardized questionnaires and structured clinical assessments across a broad range of 
psychopathological problems (such as ADOS for ASD and DAWBA), as the present study 
does. 
Our data indicate that young children with DMD exhibit higher prevalence of ASD and ID 
(neurodevelopmental disorders as defined in the DSM-5) than expected in the general 
population. In detail, 14.89% of the boys with DMD had a diagnosis of ASD, performed 
using a standardized protocol (ADOS). 
ID was found in 36.2% of the assessed boys (FSIQ < 70), and the FSIQ average level was 
80.38, more than 1 SD below the general population average, with a greater impairment of 
verbal than performance components (VIQ: 82.88; PIQ: 85.83). These findings are 
consistent with previous studies focused on cognitive and neurobehavioral profile of DMD 
conducted over the past 20 years, suggesting that the non-progressive, cognitive impairment 
does not correlate with the severity of muscle disease, and primarily involves verbal rather 
than nonverbal intelligence.8; 26; 27; 28 ;  29 A significant difference in FSIQ between the 
two sites of mutation was found (proximal FSIQ: 86.88 vs distal FSIQ: 74.62; p = .035). 
This result replicates findings of previously published studies, which show an association 
between distal DMD mutations and a more severe cognitive deficit. 9; 16; 27; 28; 29 ;  30 
Mutations in the distal portion of the DMD gene are associated with loss of cerebral 
dystrophin isoforms, which might explain the reduced intellectual functioning found among 
our DMD children with distal deletion. Dystrophin isoforms of the central nervous system 
(CNS) are in fact more expressed in the cerebellum and limbic system and play a role in 
glutaminergic synapses and in synaptic maturation and function. 31 ;  32 Support to the 
hypothesis of an association between lack of brain dystrophin and cognitive impairment is 
provided both by clinical and animal-model studies.33 Focussing on cerebellum, DMD 
patients have been reported to have cerebellar hypo-metabolism through positron emission 
tomography.34 Both neuroimaging and neuropsychological investigations provided 
evidence of the possible implication of the cerebellum in a wide range of cognitive 
functions,35 and although with fewer data, this could be true for DMD patients as well. 
Lack of dystrophin in the cerebellum may thus be the neurobiological explanation for the 
neurodevelopmental disorders observed in our group of patients, and further support to this 
hypothesis comes from a range of behavioural observations and neuroimaging investigations 
which have found evidence of a cerebellar role in two neurodevelopmental conditions: ASD 
and ADHD. Interestingly, literature provides evidence of a cerebellar contribution even to 
aspects of social emotional and regulatory behaviour, which are frequently impaired in ASD 
and ADHD. 35 ;  36 
Although the prevalence of neurodevelopmental disorders (ASD and ID) is evident, in the 
present study a broad range of emotional and behavioural problems (internalizing and 
externalizing) were also assessed: we found a remarkable number of boys who exceeded the 
clinical cut-off for CBCL Internalizing Problems (N = 11), which constitutes a high rate 
(23.4%) when compared to Italian normative data. 37 This is an interesting finding, as this 
rate is very consistent with that recently reported by Ricotti and colleagues using the same 
screening questionnaire (24% of males scored above the clinical threshold). 
In contrast to aforementioned studies, in our DMD sample no ADHD comorbidity was 
found. Some of the questions on the CBCL, SDQ, and DAWBA that address ADHD 
symptoms are not as useful, as children with DMD cannot display the same type of 
hyperactivity symptoms, such as fidgetiness, due to their motor problems, and measures 
regarding physical movement (e.g., being restless, being fidgety, running around at dinner 
time) may not be rated high if the child has limited mobility. Although these instruments 
represented a gold standard of screening and detecting psychopathology in children and 
adolescents, it is possible that they are not the best way to detect specific psychopathological 
problems in boys with DMD, given the physical limitations of such patients, which could 
result in false negatives. 
This result is both unusual and challenging: it opens interesting issues about not only 
methodology, but perhaps on the phenomenology of ADHD in the Duchenne clinical 
population. Indeed, it is important to note that, because of muscle weakness and physical 
limitations, symptoms of hyperactivity may be less obvious in DMD boys. It is likewise 
important to know that some of the cognitive patterns observed in Duchenne (such as 
language or discrete short-term memory deficits) can lead to a child being misidentified as 
having ADHD. 
To our knowledge, the assessment protocol applied in our study, providing information not 
only about emotional and behavioural problems but also on the impairment due to these 
emotional and behavioural problems, could have given useful information to define clinical 
caseness. 
Specifically, the Strength and Difficulties Questionnaire impact supplement was used to 
assess associated distress together with social, educational, and family life impairment.38 
For children with emotional/behavioural difficulties, parents and adolescents were asked to 
respond to one item about level of child distress and up to four items about interference of 
the child's emotional/behavioural problems with family life, leisure activities (both items for 
parents only), friendships, and classroom learning (all scored 0–2). Impact scores ranged 
from 0 to 10 for parents and adolescents. Goodman suggests that impact scores are better 
than symptom scores at discriminating between the community and clinic samples.20 
As outlined above, results obtained for our Institute study group replicate many findings 
from previously published studies on both cognitive deficits, association of mutation site 
with IQ, ASD prevalence and internalizing problems, using a strong and extended 
assessment protocol. 
Yet, even though rates of emotional problems (Internalizing Problems and 
Anxious/Depressed Problems) among children with DMD are higher than in the general 
population (as expected with any chronic illness), the majority of children affected do not 
have behavioural problems. Additionally, it is noteworthy that self-perception among many 
children and adolescents with DMD is more positive than what their caregivers imagine. 
Although all the children enrolled in this study live with a chronic, progressive, and 
eventually fatal neuromuscular disorder, a remarkable 67% were not found to be 
psychopathologically “at risk” by a standard child behaviour measure. A possible 
explanation, as already noted, could be the lack of assessment tools for this special clinical 
population. However, this result led to the hypothesis that these patients and their families 
may use specific coping strategies that have a positive influence on dealing with illness and 
stressful situations, and thus emotional and behavioural difficulties may become milder. In 
future research it would be interesting to investigate coping strategies in families with 
neuromuscular diseases and to develop specific emotional and behavioural measures for this 
clinical population. 
Limitations 
These results should be regarded as preliminary and with some limitations in mind. 
Firstly, we did not have a control group, whereas other studies have compared DMD 
patients with their siblings or with patients who have other neuromuscular diseases. This 
limitation will be addressed in future studies, as this observational clinical study is proposed 
to be the first step of a larger study. 
Secondly, even though this sample is appropriate for a monocentric study, the sample size is 
relatively low for the range of age and clinical phenomenology. Nevertheless, the use of 
standardized questionnaires, with a psychometric validation and normalized scores for 
gender and age (age range 6–18), should provide consistent data. Validity and reliability 
studies have shown that the CBCL 6–18 is an effective instrument for assessing emotional 
and behavioural problems in children and adolescents.17 Moreover, in this preliminary 
observational study we use validated clinical instruments that focus also on the impact of 
emotional/behavior problems on everyday life, even in the first screening (SDQ). 
Finally, additional structured interviews (i.e. ADOS and DAWBA) were administered only 
in a subsample of 18 patients (38.3% of the total sample), according to our assessment 
procedure (see Fig. 1): this may lead to an underestimation of the true rate of 
psychopathology in this special clinical population. Nevertheless, the utility of behavioural 
screening instruments for risk stratification was largely demonstrated.17 ;  39 Sheldrick 
et al. (2015) reported that children who screened positive – at CBCL 6–18 and SDQ – were 
approximately 2–5 times more likely than children who screened negative to qualify for a 
psychiatric diagnosis. 
6. Conclusions 
In the present study, 47 Italian boys with DMD were assessed for emotional and behavioural 
problems and neurobehavioral disorders. Our data indicate that young children with DMD 
exhibit higher prevalence of ASD (14.89%) and ID (36.2%) and a higher rate of CBCL 
Internalizing Problems (23.4%) than expected in the general population Yet, even though 
rates of emotional problems (Internalizing Problems and Anxious/Depressed Problems) 
among children with DMD are higher (as expected with any chronic illness), the majority of 
children affected do not have behavioural problems. Additionally, it is noteworthy that self-
perception among many children and adolescents with DMD is more positive than what 
their caregivers imagine. Even though preliminary, these data show that use of validated 
clinical instruments, that focus on the impact of emotional/behaviour problems on everyday 
life, allows to carefully identify clinically significant psychopathology. 
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